Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Leerink Partnrs has trimmed its Q2 2025 earnings estimate for Merck & Co., Inc., foreseeing a dip to $1.96 per share from ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

When torn between Envista (NVST) and Abbott (ABT) for the best value stock, one shines brighter. Envista flaunts a more appealing forward P/E ratio of 18.81 compared to Abbott's 24.16. Not just the ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Sixteen “safer” Ideal GASV emerged as buys for July. Top-ten tickers to buy were: CALM; FSK; MPLX; ET; YRD; ING; MO; VZ; NWBI ...

Pittsburgh, USA-based Viatris, which was formed in 2020 through the merger of Mylan and Pfizer's, saw its shares fall 4.2% to ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...